The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis

被引:1
|
作者
Lv, Qiong [1 ,2 ]
Zhao, Huashan [2 ,3 ,4 ,5 ]
机构
[1] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Electrocardiogram, Luoyang, Peoples R China
[2] Henan Univ Sci & Technol, Coll Clin Med, Luoyang, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, Luoyang, Peoples R China
[4] Henan Univ Sci & Technol, Affiliated Hosp 1, Dept Gen Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
[5] Henan Univ Sci & Technol, Coll Clin Med, 24 Jinghua Rd, Luoyang, Henan, Peoples R China
关键词
Association; MI; mASLD; risk factors; FATTY LIVER; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; MANAGEMENT; ELEVATION; MORTALITY;
D O I
10.1080/07853890.2024.2306192
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular disease (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis to determine the relationship between MASLD and MI risk.Methods PubMed, MEDLINE, Embase, Web of Science, CNKI, CBM, VIP, and WanFang databases were searched, and the DerSimonian Laird method was used to obtain hazard ratios (HRs) for binary variables to assess the correlation between MASLD and MI risk. Subgroup analyses for the study region, MASLD diagnosis, quality score, study design, and follow-up time were conducted simultaneously for the selected studies retrieved from the time of database establishment to March 2022. All study procedures were independently conducted by two investigators.Results The final analysis included seven articles, including eight prospective and two retrospective cohort studies. The MI risk was higher among MASLD patients than among non-MASLD patients (HR = 1.26; 95% CI: 1.08-1.47, p = 0.003). The results of the subgroup analysis of the study region revealed an association of MASLD with MI risk among Americans and Asians, but not in Europeans. Subgroup analyses of MASLD diagnosis showed that ultrasonography and other (fatty liver index[FLI] and computed tomography [CT)]) diagnostic methods, but not international classification of disease (ICD), increased the risk of MI. Subgroup analysis of the study design demonstrated a stronger relationship between MASLD and MI in retrospective studies but not in prospective studies. Subgroup analysis based on the follow-up duration revealed the association of MASLD with MI risk in cases with < 3 years of follow-up but not with >= 3 years of follow-up.Conclusion MASLD increases the risk of MI, independent of traditional risk factors.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review
    Sanyal, Arun J.
    Husain, Mansoor
    Diab, Crystel
    Mangla, Kamal Kant
    Shoeb, Ahsan
    Lingvay, Ildiko
    Tapper, Elliot B.
    [J]. AMERICAN HEART JOURNAL PLUS: CARDIOLOGY RESEARCH AND PRACTICE, 2024, 41
  • [32] Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings
    Iruzubieta, Paula
    Santos-Laso, Alvaro
    Arias-Loste, Maria Teresa
    Calleja, Jose Luis
    Crespo, Javier
    [J]. JOURNAL OF HEPATOLOGY, 2024, 80 (03) : e121 - e123
  • [33] Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Shin, Soyeon
    Kim, Jaeyoung
    Lee, Ju Yeon
    Kim, Jun
    Oh, Chang-Myung
    [J]. JOURNAL OF OBESITY & METABOLIC SYNDROME, 2023, 32 (04) : 289 - 302
  • [34] Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
    Hutchison, Alan L.
    Tavaglione, Federica
    Romeo, Stefano
    Charlton, Michael
    [J]. JOURNAL OF HEPATOLOGY, 2023, 79 (06) : 1524 - 1541
  • [35] Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis
    Mantovani, Alessandro
    Lando, Maria Giovanna
    Borella, Nicolo
    Scoccia, Enrico
    Pecoraro, Barbara
    Gobbi, Federico
    Bisoffi, Zeno
    Valenti, Luca
    Tilg, Herbert
    Byrne, Christopher D.
    Targher, Giovanni
    [J]. LIVER INTERNATIONAL, 2024, 44 (07) : 1513 - 1525
  • [36] Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights
    Aggeletopoulou, Ioanna
    Tsounis, Efthymios P.
    Triantos, Christos
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (09)
  • [37] Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies
    Zhao, Jian-Feng
    Zhou, Ben-Gang
    Lv, Yang
    Teng, Qiu-Ping
    Wang, Xi-Mei
    Li, Xiao-Yi
    Ding, Yi
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [38] A review regarding the article 'Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis. '
    Li, Chao
    Wang, Ting
    Song, Jinbo
    [J]. CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (07)
  • [39] Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor
    Platek, Anna E.
    Szymanska, Anna
    [J]. CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 187 - 192
  • [40] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    [J]. HEPATOLOGY, 2023,